Understanding Medicare’s Aduhelm Coverage Decision
Yesterday, the Facilities for Medicare and Medicaid Companies (CMS) issued a draft National Protection Willpower (NCD) proposing that monoclonal antibodies directed from amyloid for the treatment of Alzheimer’s sickness be…